New drug aims to ease symptoms of rare mast cell disease
Symptom relief
Ongoing
This phase 2 study tests whether avapritinib, a targeted drug taken as a tablet, can reduce symptoms in people with indolent systemic mastocytosis whose symptoms are not well controlled by standard care. About 251 participants will receive either avapritinib or a placebo, and all…
Phase: PHASE2 • Sponsor: Blueprint Medicines Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC